XERS - Xeris Bio's Ogluo now available in U.K. for treatment of hypoglycaemia

Xeris Biopharma (NASDAQ:XERS) announces that its commercialization partner, Tetris Pharma has launched Ogluo (glucagon injection) in the U.K. and it is now available by prescription for the treatment of severe hypoglycemia in in pediatric and adult patients aged 2 years and above with diabetes mellitus. In July, Xeris inked licensing deal with Tetris for commercialization of Ogluo (European brand name of Gvoke) in European Union. Tetris aims for Ogluo to be launched in several countries across Europe during 2022. The European Commission granted the marketing authorization Ogluo for severe hypoglycaemia in February 2021. The U.K.'s regulatory agency approved Ogluo on April 29, 2021.

For further details see:

Xeris Bio's Ogluo now available in U.K. for treatment of hypoglycaemia